Literature DB >> 18440263

Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats.

Marcus N Gunew1, Victor H Menrath, Rhett D Marshall.   

Abstract

Osteoarthritis is a chronic, painful condition that is now recognised as affecting a large proportion of cats. Non-steroidal anti-inflammatory drugs (NSAIDs) have proven efficacy in dogs and humans but there are limited published data on the use of NSAIDs in the long-term management of this condition in cats. This prospective study aimed to assess the long-term safety and palatability of oral meloxicam and its efficacy in treating osteoarthritic pain in cats when given at a dose of 0.01-0.03 mg/kg once daily. Forty cats diagnosed with osteoarthritis completed the trial with a mean treatment duration of 5.8 months. Gastrointestinal upset in 2/46 (4%) cats was the only adverse effect noted. No deleterious effect on renal function was detected in cats studied. Owners subjectively assessed treatment efficacy as good or excellent in 34/40 (85%) of cases. The results of this study showed oral meloxicam to be safe and palatable long-term treatment for osteoarthritis in cats when given with food at a dose of 0.01-0.03 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440263     DOI: 10.1016/j.jfms.2007.10.007

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  18 in total

1.  Feline orthopedics.

Authors:  Greg Harasen
Journal:  Can Vet J       Date:  2009-06       Impact factor: 1.008

2.  Efficacy and safety of 3 versus 5 days of meloxicam as an analgesic for feline onychectomy and sterilization.

Authors:  Walt Ingwersen; Ronald Fox; Gail Cunningham; Martha Winhall
Journal:  Can Vet J       Date:  2012-03       Impact factor: 1.008

3.  Owner-perceived signs and veterinary diagnosis in 50 cases of feline osteoarthritis.

Authors:  Mary P Klinck; Diane Frank; Martin Guillot; Eric Troncy
Journal:  Can Vet J       Date:  2012-11       Impact factor: 1.008

4.  Meloxicam prevents COX-2-mediated post-surgical inflammation but not pain following laparotomy in mice.

Authors:  J V Roughan; H G M J Bertrand; H M Isles
Journal:  Eur J Pain       Date:  2015-04-23       Impact factor: 3.931

5.  Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Copolymers for the Formulation of In Situ Forming Depot Long-Acting Injectables.

Authors:  Marie-Emérentienne Cagnon; Silvio Curia; Juliette Serindoux; Jean-Manuel Cros; Feifei Ng; Adolfo Lopez-Noriega
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

6.  Criterion Validation Testing of Clinical Metrology Instruments for Measuring Degenerative Joint Disease Associated Mobility Impairment in Cats.

Authors:  Margaret E Gruen; Emily H Griffith; Andrea E Thomson; Wendy Simpson; B Duncan X Lascelles
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

7.  Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis.

Authors:  Beatriz P Monteiro; Mary P Klinck; Maxim Moreau; Martin Guillot; Paulo V M Steagall; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Dominique Gauvin; Jérôme R E Del Castillo; Eric Troncy
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

8.  Preliminary Validation and Reliability Testing of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians, in a Colony of Laboratory Cats.

Authors:  Mary P Klinck; Pascale Rialland; Martin Guillot; Maxim Moreau; Diane Frank; Eric Troncy
Journal:  Animals (Basel)       Date:  2015-12-02       Impact factor: 2.752

9.  Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.

Authors:  Jonathan N King; Alessandro Panteri; Melanie Graille; Wolfgang Seewald; Gabriele Friton; Cyril Desevaux
Journal:  BMC Vet Res       Date:  2016-06-23       Impact factor: 2.741

10.  A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study.

Authors:  M E Gruen; A E Thomson; E H Griffith; H Paradise; D P Gearing; B D X Lascelles
Journal:  J Vet Intern Med       Date:  2016-06-22       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.